Doxorubicin-loading Core-shell Pectin Nanocell: A Novel Nanovehicle for Anticancer Agent Delivery with Multidrug Resistance Reversal

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2020 Jun 23

PMID 32569270

Citations 3

Authors

Jiabi Ouyang

Mohui Yang

Tian Gong

Jinlai Ou

Yani Tan

Zhen Zhang

Sha Li

Affiliations

Soon will be listed here.

Abstract

Tumor is a prevalent great threat to public health worldwide and multidrug resistance (MDR) of tumor is a leading cause of chemotherapy failure. Nanomedicine has shown prospects in overcoming the problem. Doxorubicin (DOX), a broad-spectrum anticancer drug, showed limited efficacy due to MDR. Herein, a doxorubicin containing pectin nanocell (DOX-PEC-NC) of core-shell structure, a pectin nanoparticle encapsulated with liposome-like membrane was developed. The DOX-PEC-NC, spheroid in shape and sized around 150 nm, exerted better sustained release behavior than doxorubicin loading pectin nanoparticle (DOX-PEC-NP) or liposome (DOX-LIP). In vitro anticancer study showed marked accumulation of doxorubicin in different tumor cells as well as reversal of MDR in HepG2/ADR cells and MCF-7/ADR cells caused by treatment of DOX-PEC-NC. In H22 tumor-bearing mice, DOX-PEC-NC showed higher anticancer efficacy and lower toxicity than doxorubicin. DOX-PEC-NC can improve anticancer activity and reduce side effect of doxorubicin due to increased intracellular accumulation and reversal of MDR in tumor cells, which may be a promising nanoscale drug delivery vehicle for chemotherapeutic agents.

Citing Articles

Pectin a multifaceted biopolymer in the management of cancer: A review.

Picot-Allain M, Neergheen V Heliyon. 2023; 9(11):e22236.

PMID: 38058641 PMC: 10696011. DOI: 10.1016/j.heliyon.2023.e22236.

Preparation and Characterization of Hydrogel Films and Nanoparticles Based on Low-Esterified Pectin for Anticancer Applications.

Patlay A, Belousov A, Silantev V, Shatilov R, Shmelev M, Kovalev V Polymers (Basel). 2023; 15(15).

PMID: 37571174 PMC: 10422365. DOI: 10.3390/polym15153280.

Pharmaceutical and drug delivery applications of pectin and its modified nanocomposites.

Kedir W, Deresa E, Diriba T Heliyon. 2022; 8(9):e10654.

PMID: 36164543 PMC: 9508417. DOI: 10.1016/j.heliyon.2022.e10654.

References

Khanniri E, Bagheripoor-Fallah N, Sohrabvandi S, Mortazavian A, Khosravi-Darani K, Mohammad R . Application of Liposomes in Some Dairy Products. Crit Rev Food Sci Nutr. 2015; 56(3):484-93. DOI: 10.1080/10408398.2013.779571. View

Arias J . Novel strategies to improve the anticancer action of 5-fluorouracil by using drug delivery systems. Molecules. 2008; 13(10):2340-69. PMC: 6245407. DOI: 10.3390/molecules13102340. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1):7-34. DOI: 10.3322/caac.21551. View

Thakkar S, Sharma D, Kalia K, Tekade R . Tumor microenvironment targeted nanotherapeutics for cancer therapy and diagnosis: A review. Acta Biomater. 2019; 101:43-68. DOI: 10.1016/j.actbio.2019.09.009. View

Klemetsrud T, Jonassen H, Hiorth M, Kjoniksen A, Smistad G . Studies on pectin-coated liposomes and their interaction with mucin. Colloids Surf B Biointerfaces. 2012; 103:158-65. DOI: 10.1016/j.colsurfb.2012.10.012. View

Kumar A, Jaitak V . Natural products as multidrug resistance modulators in cancer. Eur J Med Chem. 2019; 176:268-291. DOI: 10.1016/j.ejmech.2019.05.027. View

Liu L, Fishman M, Kost J, Hicks K . Pectin-based systems for colon-specific drug delivery via oral route. Biomaterials. 2003; 24(19):3333-43. DOI: 10.1016/s0142-9612(03)00213-8. View

Gu Y, Cheng J, Man C, Wong W, Cheng S . Gold-doxorubicin nanoconjugates for overcoming multidrug resistance. Nanomedicine. 2011; 8(2):204-11. DOI: 10.1016/j.nano.2011.06.005. View

Maeki M, Kimura N, Sato Y, Harashima H, Tokeshi M . Advances in microfluidics for lipid nanoparticles and extracellular vesicles and applications in drug delivery systems. Adv Drug Deliv Rev. 2018; 128:84-100. DOI: 10.1016/j.addr.2018.03.008. View

10.

Ambudkar S, Kimchi-Sarfaty C, Sauna Z, Gottesman M . P-glycoprotein: from genomics to mechanism. Oncogene. 2003; 22(47):7468-85. DOI: 10.1038/sj.onc.1206948. View

11.

Rodrigues A, Matos J, Nova Dias A, Almeida B, Pires A, Pereira A . Development of Multifunctional Liposomes Containing Magnetic/Plasmonic MnFe₂O₄/Au Core/Shell Nanoparticles. Pharmaceutics. 2019; 11(1). PMC: 6358969. DOI: 10.3390/pharmaceutics11010010. View

12.

Renu K, V G A, P B T, Arunachalam S . Molecular mechanism of doxorubicin-induced cardiomyopathy - An update. Eur J Pharmacol. 2017; 818:241-253. DOI: 10.1016/j.ejphar.2017.10.043. View

13.

Deng Z, Yan F, Jin Q, Li F, Wu J, Liu X . Reversal of multidrug resistance phenotype in human breast cancer cells using doxorubicin-liposome-microbubble complexes assisted by ultrasound. J Control Release. 2013; 174:109-16. DOI: 10.1016/j.jconrel.2013.11.018. View

14.

Tao J, Fei W, Tang H, Li C, Mu C, Zheng H . Angiopep-2-Conjugated "Core-Shell" Hybrid Nanovehicles for Targeted and pH-Triggered Delivery of Arsenic Trioxide into Glioma. Mol Pharm. 2019; 16(2):786-797. DOI: 10.1021/acs.molpharmaceut.8b01056. View

15.

Gungor-Ordueri N, Kuscu N, Tasatargil A, Burgucu D, Karacan M, Celik-Ozenci C . Doxorubicin-induced testicular damage is related to PARP-1 signaling molecules in mice. Pharmacol Rep. 2019; 71(4):591-602. DOI: 10.1016/j.pharep.2019.02.018. View

16.

Szakacs G, Paterson J, Ludwig J, Booth-Genthe C, Gottesman M . Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006; 5(3):219-34. DOI: 10.1038/nrd1984. View

17.

Li L, Zhou M, Huang Y . Synergistic enhancement of anticancer therapeutic efficacy of HPMA copolymer doxorubicin conjugates via combination of ligand modification and stimuli-response srategies. Int J Pharm. 2017; 536(1):450-458. DOI: 10.1016/j.ijpharm.2017.12.018. View

18.

Kibria G, Hatakeyama H, Harashima H . Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system. Arch Pharm Res. 2013; 37(1):4-15. DOI: 10.1007/s12272-013-0276-2. View

19.

Betancourt T, Brown B, Brannon-Peppas L . Doxorubicin-loaded PLGA nanoparticles by nanoprecipitation: preparation, characterization and in vitro evaluation. Nanomedicine (Lond). 2007; 2(2):219-32. DOI: 10.2217/17435889.2.2.219. View

20.

Sengupta S, Eavarone D, Capila I, Zhao G, Watson N, Kiziltepe T . Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature. 2005; 436(7050):568-72. DOI: 10.1038/nature03794. View